norethisterone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids, progestogens 1962 68-22-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • norethindrone
  • norethisteron
  • norethisterone
  • norethynodrone
A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.
  • Molecular weight: 298.43
  • Formula: C20H26O2
  • CLOGP: 2.79
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -4.65
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg P
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.02 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 64 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
May 21, 1962 FDA ORTHO MCNEIL PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal haemorrhage 124.73 17.99 59 6311 27428 63455224
Hepatic adenoma 101.02 17.99 19 6351 324 63482328
Prostatic disorder 69.94 17.99 11 6359 59 63482593
Heavy menstrual bleeding 65.16 17.99 33 6337 17740 63464912
Endometriosis 56.69 17.99 21 6349 5299 63477353
Superior sagittal sinus thrombosis 48.31 17.99 12 6358 779 63481873
Aplastic anaemia 47.89 17.99 22 6348 9547 63473105
Metaplasia 47.84 17.99 11 6359 513 63482139
Purpura 47.24 17.99 23 6347 11362 63471290
Pelvic pain 46.35 17.99 24 6346 13495 63469157
Intermenstrual bleeding 45.32 17.99 20 6350 7906 63474746
Cerebral venous sinus thrombosis 41.62 17.99 13 6357 1959 63480693
Pregnancy on oral contraceptive 40.38 17.99 11 6359 1026 63481626
Transfusion 38.25 17.99 22 6348 15195 63467457
Exposure to allergen 35.94 17.99 8 6362 322 63482330
Ovarian atrophy 32.44 17.99 6 6364 93 63482559
Drug-induced liver injury 32.28 17.99 29 6341 40193 63442459
Uterine perforation 31.72 17.99 15 6355 6948 63475704
Rash erythematous 30.90 17.99 29 6341 42481 63440171
Hereditary angioedema 30.54 17.99 15 6355 7547 63475105
Rash maculo-papular 29.63 17.99 25 6345 31871 63450781
Genital burning sensation 25.96 17.99 6 6364 286 63482366
Product dose omission issue 25.78 17.99 66 6304 234247 63248405
Febrile neutropenia 24.26 17.99 43 6327 118406 63364246
Haemorrhage 23.84 17.99 30 6340 60992 63421660
Blood iron decreased 23.62 17.99 16 6354 14705 63467947
Vaginal ulceration 23.57 17.99 6 6364 430 63482222
Hot flush 23.00 17.99 27 6343 51132 63431520
Rectal haemorrhage 22.24 17.99 26 6344 49004 63433648
Hepatic rupture 21.50 17.99 4 6366 64 63482588
Lip exfoliation 21.34 17.99 6 6364 629 63482023
Acne 21.10 17.99 18 6352 23275 63459377
Peliosis hepatis 20.96 17.99 4 6366 74 63482578
Dilatation intrahepatic duct acquired 20.88 17.99 6 6364 680 63481972
Melaena 20.70 17.99 20 6350 30345 63452307
Menstruation irregular 19.97 17.99 11 6359 6993 63475659
Mast cell activation syndrome 19.79 17.99 6 6364 819 63481833
Device dislocation 19.57 17.99 18 6352 25687 63456965
Haemoglobin decreased 19.21 17.99 44 6326 145441 63337211
Depression 18.23 17.99 52 6318 196440 63286212
Abortion spontaneous 18.11 17.99 23 6347 47172 63435480

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal haemorrhage 139.29 19.84 52 4900 21765 79717671
Metaplasia 126.38 19.84 23 4929 539 79738897
Prostatic disorder 95.51 19.84 23 4929 2137 79737299
Hepatic adenoma 90.13 19.84 16 4936 324 79739112
Heavy menstrual bleeding 63.26 19.84 26 4926 13985 79725451
Superior sagittal sinus thrombosis 50.52 19.84 12 4940 1051 79738385
Purpura 43.02 19.84 22 4930 19505 79719931
Pregnancy on oral contraceptive 42.56 19.84 10 4942 835 79738601
Aplastic anaemia 41.86 19.84 21 4931 17884 79721552
Cerebral venous sinus thrombosis 41.38 19.84 12 4940 2279 79737157
Pelvic pain 41.33 19.84 19 4933 13362 79726074
Transfusion 41.19 19.84 22 4930 21308 79718128
Intermenstrual bleeding 41.11 19.84 15 4937 5869 79733567
Exposure to allergen 39.50 19.84 8 4944 333 79739103
Drug-induced liver injury 37.89 19.84 32 4920 66085 79673351
Uterine perforation 36.49 19.84 14 4938 6289 79733147
Endometriosis 35.81 19.84 12 4940 3656 79735780
Ovarian atrophy 35.56 19.84 6 4946 89 79739347
Vaginal ulceration 29.11 19.84 6 4946 273 79739163
Genital burning sensation 28.14 19.84 6 4946 322 79739114
Blood iron decreased 27.24 19.84 15 4937 15419 79724017
Rash erythematous 27.17 19.84 25 4927 57744 79681692
Rash maculo-papular 23.94 19.84 23 4929 56055 79683381
Lip exfoliation 23.89 19.84 6 4946 662 79738774
Ovarian failure 23.82 19.84 6 4946 670 79738766
Dilatation intrahepatic duct acquired 23.30 19.84 6 4946 732 79738704
Complication of device insertion 22.74 19.84 10 4942 6340 79733096
Device dislocation 22.35 19.84 16 4936 25954 79713482
Maternal exposure during pregnancy 21.76 19.84 34 4918 136504 79602932
Acne 21.69 19.84 16 4936 27174 79712262
Hepatic rupture 21.50 19.84 4 4948 106 79739330
Peliosis hepatis 20.45 19.84 4 4948 139 79739297
Migraine 20.18 19.84 26 4926 87467 79651969

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03AA05 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AB04 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AC01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens
ATC G03DC02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS
Estren derivatives
ATC G03FA01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, fixed combinations
ATC G03FB05 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, sequential preparations
ATC H01CC53 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
HYPOTHALAMIC HORMONES
Anti-gonadotropin-releasing hormones
ATC H01CC54 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
HYPOTHALAMIC HORMONES
Anti-gonadotropin-releasing hormones
FDA CS M0447349 Progesterone Congeners
FDA Chemical/Ingredient N0000011301 Progesterone Congeners
MeSH PA D003270 Contraceptive Agents
MeSH PA D003271 Contraceptive Agents, Female
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D003278 Contraceptives, Oral, Hormonal
MeSH PA D003280 Contraceptives, Oral, Synthetic
MeSH PA D012102 Reproductive Control Agents
CHEBI has role CHEBI:49326 synthetic oral contraceptives
CHEBI has role CHEBI:59826 progestins
FDA EPC N0000175602 Progestin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Contraception indication 13197004
Female hypogonadism syndrome indication 16041008
Dysfunctional uterine bleeding indication 19155002
Atrophic vaginitis indication 52441000
Primary ovarian failure indication 65846009
Secondary physiologic amenorrhea indication 86030004
Acne vulgaris indication 88616000
Postmenopausal osteoporosis indication 102447009
Vasomotor symptoms associated with climacteric disturbance indication 123756000
Endometriosis indication 129103003
Menopausal flushing indication 198436008
Atrophic vulva indication 248861000 DOID:14275
Menorrhagia indication 386692008
Controlled ovarian stimulation indication 732970000
Vasomotor symptoms associated with ovarian deficiency symptoms indication
Amenorrhea off-label use 14302001 DOID:13938
Polycystic ovaries off-label use 69878008
Dysmenorrhea off-label use 266599000
Abnormal uterine bleeding unrelated to menstrual cycle off-label use 312984006
Heart valve disorder contraindication 368009 DOID:4079
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Benign mammary dysplasia contraindication 57993004
Obstructive hyperbilirubinemia contraindication 59848001
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Uterine leiomyoma contraindication 95315005 DOID:13223
Deep venous thrombosis contraindication 128053003
Liver function tests abnormal contraindication 166603001
Mammography abnormal contraindication 168750009
Angina pectoris contraindication 194828000
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Endometrial carcinoma contraindication 254878006 DOID:2871
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of cervix contraindication 363354003 DOID:4362
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Optic disc edema contraindication 423341008 DOID:146
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Major Surgery with Prolonged Post-Operative Immobilization contraindication
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor AGONIST ED50 11.26 WOMBAT-PK CHEMBL
Glucocorticoid receptor Nuclear hormone receptor Ki 6.71 DRUG MATRIX
Estrogen receptor Nuclear hormone receptor Ki 6.64 DRUG MATRIX
Androgen receptor Nuclear hormone receptor IC50 7.12 WOMBAT-PK
Sex hormone-binding globulin Secreted Kd 7.97 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.62 DRUG MATRIX
Androgen receptor Transcription factor IC50 6.92 CHEMBL
Progesterone receptor Transcription factor Ki 8.91 DRUG MATRIX
Estrogen receptor Transcription factor Kd 9.20 CHEMBL

External reference:

IDSource
4018496 VUID
N0000146818 NUI
D00182 KEGG_DRUG
4018496 VANDF
C0028356 UMLSCUI
CHEBI:7627 CHEBI
CHEMBL1162 ChEMBL_ID
DB00717 DRUGBANK_ID
2880 IUPHAR_LIGAND_ID
6230 PUBCHEM_CID
7514 RXNORM
182290 MMSL
5187 MMSL
d00555 MMSL
001298 NDDF
001326 NDDF
126102009 SNOMEDCT_US
63758001 SNOMEDCT_US
D009640 MESH_DESCRIPTOR_UI
NDR PDB_CHEM_ID
687 INN_ID
T18F433X4S UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Norethindrone HUMAN PRESCRIPTION DRUG LABEL 1 0378-7272 TABLET 0.35 mg ORAL ANDA 14 sections
Norethindrone HUMAN PRESCRIPTION DRUG LABEL 1 0378-7272 TABLET 0.35 mg ORAL ANDA 14 sections
Norethindrone HUMAN PRESCRIPTION DRUG LABEL 1 0378-7272 TABLET 0.35 mg ORAL ANDA 14 sections
NORETHINDRONE HUMAN PRESCRIPTION DRUG LABEL 1 0378-7292 TABLET 0.35 mg ORAL ANDA 14 sections
Nortrel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9009 TABLET 1 mg ORAL ANDA 21 sections
Nortrel21 Day HUMAN PRESCRIPTION DRUG LABEL 2 0555-9009 TABLET 1 mg ORAL ANDA 21 sections
NORETHINDRONE HUMAN PRESCRIPTION DRUG LABEL 1 50090-6161 TABLET 0.35 mg ORAL ANDA 13 sections
LYZA HUMAN PRESCRIPTION DRUG LABEL 1 50102-100 TABLET 0.35 mg ORAL ANDA 13 sections
Tulana Human Prescription Drug Label 1 50102-200 TABLET 0.35 mg ORAL ANDA 14 sections
Lyleq Human Prescription Drug Label 1 50102-300 TABLET 0.35 mg ORAL ANDA 14 sections
Lyleq Human Prescription Drug Label 1 50102-300 TABLET 0.35 mg ORAL ANDA 14 sections
Ortho Micronor HUMAN PRESCRIPTION DRUG LABEL 1 50458-194 TABLET 0.35 mg ORAL NDA 24 sections
NORLYROC HUMAN PRESCRIPTION DRUG LABEL 1 51660-127 TABLET, FILM COATED 0.35 mg ORAL ANDA 12 sections
CAMILA HUMAN PRESCRIPTION DRUG LABEL 1 51862-884 TABLET 0.35 mg ORAL ANDA 25 sections
ERRIN HUMAN PRESCRIPTION DRUG LABEL 1 51862-886 TABLET 0.35 mg ORAL ANDA 26 sections
ERRIN HUMAN PRESCRIPTION DRUG LABEL 1 51862-886 TABLET 0.35 mg ORAL ANDA 26 sections
Nora BE HUMAN PRESCRIPTION DRUG LABEL 1 52544-629 TABLET 0.35 mg ORAL NDA authorized generic 19 sections
Nora BE HUMAN PRESCRIPTION DRUG LABEL 1 52544-629 TABLET 0.35 mg ORAL NDA authorized generic 19 sections
Nora BE HUMAN PRESCRIPTION DRUG LABEL 1 52544-629 TABLET 0.35 mg ORAL NDA authorized generic 19 sections
Jolivette HUMAN PRESCRIPTION DRUG LABEL 1 52544-892 TABLET 0.35 mg ORAL NDA 27 sections
Lyleq Human Prescription Drug Label 1 53002-1793 TABLET 0.35 mg ORAL ANDA 14 sections
Tulana Human Prescription Drug Label 1 53002-2687 TABLET 0.35 mg ORAL ANDA 14 sections
MICRONOR HUMAN PRESCRIPTION DRUG LABEL 1 54868-4369 TABLET 0.35 mg ORAL NDA 14 sections
Camila HUMAN PRESCRIPTION DRUG LABEL 1 54868-4814 TABLET 0.35 mg ORAL ANDA 15 sections
NORETHINDRONE HUMAN PRESCRIPTION DRUG LABEL 1 57297-876 TABLET 0.35 mg ORAL ANDA 13 sections
Jencycla HUMAN PRESCRIPTION DRUG LABEL 1 57297-877 TABLET 0.35 mg ORAL ANDA 14 sections
Emzahh Human Prescription Drug Label 1 59651-136 TABLET 0.35 mg ORAL ANDA 21 sections
Norethindrone HUMAN PRESCRIPTION DRUG LABEL 1 63187-748 TABLET 0.35 mg ORAL ANDA 24 sections
Incassia Human Prescription Drug Label 1 65862-925 TABLET 0.35 mg ORAL ANDA 14 sections
AMABELZ HUMAN PRESCRIPTION DRUG LABEL 2 68180-829 TABLET 0.10 mg ORAL ANDA 30 sections